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To the Editor: Melioidosis is increasingly being rec-
ognized in tropical and subtropical areas worldwide; the 
world’s 2 major endemic foci are Thailand and northern 
Australia (1,2). Phylogenetic analyses of Burkholderia 
pseudomallei isolates, performed by using multilocus se-
quence typing (MLST) (3), have led to phylogeographic 
associations that can be used to track melioidosis epidem-
ics (4). However, in contrast to the previous separation of 
B. pseudomallei into 2 phylogenetic groups (Australia and 
Southeast Asia/rest of the world) (5), we report an MLST 
sequence type (ST) that seems to be present in northern 
Australia, Taiwan, and southern China.
In mainland China, melioidosis was first reported in 
1990 (6) and is now known to be endemic to several tropi-
cal provinces, including Hainan, a southern island province 
close to Southeast Asia. Since 2008, cases of melioidosis in 
Hainan have escalated; from July 2008 through July 2012, 
a total of 110 cases were microbiologically diagnosed at 
2 general hospitals (Sanya People’s Hospital and Haikou 
Municipal Hospital). 
We characterized clinical isolates of B. pseudomallei 
from the 110 cases by using MLST, pulsed-field gel elec-
trophoresis (PFGE), and 4-locus multilocus variable-number 
tandem-repeat analysis (MLVA-4) (3,7,8). MLST revealed 
40 STs, 39 of which were consistent with STs from Southeast 
Asia, as evident from the global B. pseudomallei MLST da-
tabase (http://bpseudomallei.mlst.net/). A single ST, ST562, 
which accounted for 3 cases in Hainan, was previously de-
scribed on the global database as being from Australia; the 20 
isolates from humans and 10 isolates from the environment 
deposited until September 1, 2014, all from Australia, had 
been isolated from 2005 through 2012. Although not depos-
ited in the global MLST database, ST562 has also recently 
been reported from Taiwan (7). Among the 253 isolates of B. 
pseudomallei collected in Taiwan during 2004–2010, 1 clini-
cal isolate and 9 environmental isolates were described as 
being ST562. Moreover, these 10 ST562 isolates displayed a 
unique PFGE pulsotype, distinct from that of other B. pseu-
domallei strains from Taiwan (7).
Of the 3 patients from Hainan from whom ST562 
strains were isolated, 2 resided in the city of Sanya and 1 
in the neighboring city of Lingshui (online Technical Ap-
pendix, http://wwwnc.cdc.gov/EID/article/21/1/14-0156- 
Techapp1.pdf); all denied a history of foreign travel, they 
shared no common risk factors, and all survived the in-
fection. Further analysis of ST562, performed by using 
eBURST-based (http://eburst.mlst.net/) population analy-
sis of the MLST dataset, showed that ST562 is a single-lo-
cus variant of ST167, which is represented on the MLST 
dataset by multiple human and environmental isolates 
from Thailand and to date by 1 human isolate from Cam-
bodia. ST167 accounted for 1 of the 110 B. pseudomallei 
strains from Hainan. The narK locus of ST167contains 
allele 3 instead of allele 29, as seen in ST562; 3 base dif-
ferences are found in allele 3: C72T (C→T position 72), 
C126T, and A435G. According to PFGE, the 3 ST562 
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isolates from Hainan displayed a single pulsotype, and 
the other 107 isolates from Hainan belonged to distinct 
and diverse pulsotypes, similar to those observed in Tai-
wan. The uniformity of PFGE patterns in the Hainan and 
Taiwan isolates supports the possibility that ST562 might 
be a recently emerging clone. PFGE patterns of Hainan 
ST562 exhibited 86% similarity with ST167, differing by 
6 bands (Figure).
Hainan ST562 isolates were further analyzed by us-
ing MLVA-4 (8), which divided 3 isolates (from patients 
A, B, and C) into 3 distinct MLVA-4 types (Figure). The 
2008 isolate (MLVA-4 profile 11,8,15,7) and one 2012 
isolate (profile 11,8,17,7) exhibited close relatedness, 
whereas another 2012 isolate (profile 10,10,11,5) was 
divergent from these, indicating that ST562 isolates in 
Hainan have been present long enough for some diver-
gence into lineages.
Two mutually exclusive gene clusters, B. thailand-
ensis–like flagellar gene cluster (BTFC) and Yersinia-like 
fimbrial gene cluster (YLF), have been linked to geo-
graphic origin and have been suggested for differentiat-
ing groups of B. pseudomallei (9). By PCR we found that 
ST562 isolates of Hainan were all YLF positive. BTFC pre-
dominates in Australian B. pseudomallei strains, and YLF 
predominates in Southeast Asia. Presence of YLF was also 
observed in strains from Papua New Guinea, possibly re-
flecting that country’s location, intermediate between ma-
jor foci of melioidosis (10).
In conclusion, by using MLST and the online MLST 
database, we revealed that B. pseudomallei ST562 is pres-
ent in southern China as well as in Australia and Taiwan. 
The intercontinental character of this ST raises new ques-
tions about the epidemiology and control of melioidosis. 
Given the usual geographic separation of B. pseudomallei 
STs, we suggest that this wide-ranging presence of ST562 
might result from more recent spread caused by transmis-
sion between regions. Increasing farming exchanges and 
trade of agricultural products between melioidosis-endemic 
regions might facilitate breaking of the geographic barrier; 
clonal introduction of B. pseudomallei could potentially 
occur in new locations. Improved and cooperative surveil-
lance is required for elucidating the current and future glob-
al dispersion range of B. pseudomallei and for monitoring 
the consequent melioidosis infections.
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Figure. Pulsed-field gel electrophoresis (PFGE) patterns for 3 sequence type (ST) 562 and 1 ST167 Burkholderia pseudomallei strains 
isolated during 2008–2012, Hainan, China. The isolate source, isolation time, ST, and 4-locus multilocus variable-number tandem-repeat 
analysis (4-MLVA) profiles are indicated for each strain. Scale bar indicates percentage similarity.
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To the Editor: Gastroenteritis caused by Shiga toxin–
producing Escherichia coli (STEC), associated with hemor-
rhagic colitis and hemolytic uremic syndrome (HUS), has 
been identified as a major health problem (1). Shiga toxin is 
essential for the development of HUS (2). Shiga toxin can 
be distinguished into Shiga toxin 1 (Stx1) and Shiga toxin 2 
(Stx2). The stx2f STEC variant is a distinct group within STEC 
(regarding virulence genes) and is known to cause relatively 
mild disease, although reports of human illness are scarce (3).
During autumn 2013, a healthy 9-year-old boy in the 
Netherlands experienced fever, vomiting, and bloody diar-
rhea which persisted for days; he was admitted to the pe-
diatric ward of a local hospital because of clinical signs of 
HUS with renal insufficiency: serum creatinine level 439 
µmol/L (reference range 31–68 µmol/L); blood urea nitro-
gen concentration 34.1 mmol/L (reference range 3.3–5.6 
mmol/L); thrombocytopenia (46 platelets/nL); reference 
range 150–450/nL), and low haptoglobin level. Hemoglo-
bin levels decreased within 48 hours from 7.4 mmol/L to 5.5 
mmol/L (reference range 6.9–8.4 mmol/L). His blood pres-
sure was 127/82 (99th percentile for age and height). Renal 
insufficiency worsened over time, evidenced by maximum 
urea levels of 57.3 mmol/L and maximum creatinine levels 
of 744 µmol/L. Vomiting increased, and feeding became dif-
ficult. The boy was transferred to an academic nephrology 
center, where he received erythrocyte and thrombocyte infu-
sions, then peritoneal dialysis. He received 1 prophylactic 
dose of cefazolin during insertion of the dialysis catheter. 
After 2 days, he entered a polyuric phase of renal failure; 
renal function normalized within a few weeks, however. To 
improve proteinuria, physicians prescribed a 3-month course 
of angiotensin-converting enzyme inhibitors after discharge.
A fecal sample tested positive for STEC by PCR in 
a local laboratory. Five isolates were sent to the National 
Institute for Public Health and the Environment (RIVM) as 
part of the national STEC surveillance. By using PCR, 1 of 
the 5 tested positive for the stx2f gene and the attaching and 
effacing gene (eae), and negative for the genes stx1, stx2a-e, 
H7, O157, and enterohemorrhagic E. coli hemolysin (hly). 
Serotyping identified O8:H19. The other 4 isolates tested 
negative for all of the above-mentioned genes and were 
not serotyped.
The family had stayed in a hotel in Turkey and re-
turned to the Netherlands 5 days before onset of illness. 
The only reported contact with animals was with a parrot in 
the hotel. On return to the Netherlands, the boy had eaten 
filet américain, a sandwich spread made of raw beef. The 
day before disease onset, he attended a party where barbe-
cue was served by a catering company.
Since 2007, besides this reported case, 8 cases of 
STEC O8 were registered within the STEC surveillance 
system in the Netherlands: O8:H– (4 cases), O8:H19 (2 
cases), O8:H8 (1 case), and O8:H9 (1 case). All 8 isolates 
were stx2a-e-positive and stx1-, stx2f-, eae-, and hly-nega-
tive. Disease associated with these cases was relatively 
mild. During 2007–2010, a total of 13,545 human STEC 
infections were reported in Europe: 20 were registered 
as STEC O8; HUS did not develop in these case-patients 
(4). HUS developed in 2 patients infected with STEC O8 
(O8:H2, O8:H19) in Germany during 1996–2000 (5); 
these isolates and all other isolates from HUS and non-
HUS case-patients in this period tested negative for stx2f. 
During 2008–2011, 87 stx2f STEC infections were regis-
tered in the Netherlands (3). These infections were rela-
tively mild; no HUS cases were registered. The virulence 
genes seen in the isolate of the described case, stx2f and 
eae, but no hly or other toxin genes, were also seen in 97% 
of stx2f STEC infections reported in the Netherlands (3). 
Besides being detected in humans, stx2f STEC has only 
been detected in pigeons (6). 
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